newsfilter
← Latest News
GlobeNewswire·

Indivior Provides Full-Year 2026 Financial Guidance and Business Update

INDV
  • Indivior PLC announced full-year 2026 financial guidance on January 8, 2026.
  • Total net revenue is expected to range between $1,125 million & $1,195 million.
  • Total SUBLOCADE net revenue is projected to fall within the range of $905 million to $945 million.
  • Non-GAAP operating expenses are forecasted to be between $430 million & $450 million.
  • Adjusted EBITDA is anticipated to range from $535 million to $575 million.
  • At the midpoint of guidance, SUBLOCADE net revenue growth is expected to reach 11% while adjusted EBITDA grows by 35%.
  • The company entered Phase II of its Action Agenda titled "Accelerate" on January 1, 2026, focusing on dispense unit growth & margin expansion.
  • Phase I of the Action Agenda resulted in expected annual non-GAAP operating expense savings of at least $150 million.
  • Indivior gained inclusion in the S&P SmallCap 600 index effective December 22, 2025.
  • Shareholders approved a change in domicile from the U.K. to the U.S., with the new parent company Indivior Pharmaceuticals, Inc. set to take effect on January 26, 2026.
  • The company concluded a U.S. Department of Justice matter by paying the full $295 million obligation.